Standard & Poor's
http://www2.standardandpoors.comStandard & Poor’s, a division of McGraw-Hill (NYSE: MHP), produces financial research and analysis on stocks and bonds. It provides credit ratings on public and private corporations and is designated as a Nationally Recognized Statistical Rating Organization (NRSRO) by the SEC. The firm’s long-term credit ratings range from “AAA” to “D” and its short-term credit ratings range from “A-1” to “D”. Standard & Poor’s also publishes indexes including the S&P 500.
View Older Stories
-
RBC's biotech survey shows investors more bearish vs. last time
-
Jefferies recommends a tactical long on this beaten-down sector
-
Morgan Stanley is no longer long this 'poor' performing popular ETF
-
Morgan Stanley makes changes to its mid-cap equity portfolio
-
The dip in this biotech name is a "tactical buying opportunity" - Mizuho Securities
-
SPDR S&P Biotech ETF (XBI) option IV low into ASCO 2023
-
SPDR S&P Biotech ETF (XBI) sees strength amid more deal headlines
-
Biotechs Trade at a "Very Attractive Discount", Set for "Outperformance in 2022" - Analyst Defends Biotechnology Sector in the Face of Weakness
-
SPDR S&P Biotech ETF (XBI) call put ratio 2.6 calls to 1 put with focus on May 95 calls
-
Stocks with Implied Volatility Movement
-
SPDR S&P Biotech ETF (XBI) option implied volatility flat
-
SPDR S&P Biotech ETF (XBI) call put ratio 4.4 calls to 1 put as shares rally 2%
-
SPDR S&P Biotech ETF (XBI) IV flat at 38
-
SPDR S&P Biotech ETF (XBI) more calls than puts as shares at upper end of range
-
SPDR S&P Biotech ETF (XBI) puts more active than calls amid shares near record high
-
Biotech ETF (IBB) Lower After Biogen (BIIB) FDA Panel Negative Vote on Question 1
-
SPDR S&P Biotech ETF (XBI) puts more active than calls
-
SPDR S&P Biotech ETF (XBI) January put spreaders active into election results
-
Biotech ETFs Decline
-
SPDR S&P Biotech ETF (XBI) option implied volatility at low end of range as shares near four-month high
-
SPDR S&P Biotech ETF (XBI) call put ratio 3 calls to 1 put with focus on February 85 calls into expiration
-
SPDR S&P Biotech ETF (XBI) put active into 37th Annual J.P. Morgan Healthcare Conference
-
SPDR S&P Biotech ETF (XBI) call put ratio call put ratio 1 call to 5.8 puts with focus on November 67, 70 and 75 puts
-
Appaloosa LP's 13F Shows Increase in Ally (ALLY), Apple (AAPL), Micron (MU) (More...)
-
SPDR S&P Biotech ETF (XBI), iShares Nasdaq Biotechnology (IBB) Continue to Fade Following Trump Comments
-
Chardan Capital Markets Downgrades Intellia Therapeutics (NTLA) to Neutral
-
Appaloosa Management's 13F Shows New Stakes in Southwestern Energy (SWN), Chesapeake Energy (CHK), Alibaba (BABA), Increase in Western Digital (WDC), Decrease in GM (GM) (more...)
-
Biotech Sector Remains Undervalued - Oppenheimer
-
SPDR S&P Biotech ETF (XBI) volatility increases as shares rally 1.4%
-
SPDR S&P Biotech ETF (XBI) call put ratio 1.01 calls to 1 put as shares rally 3.6%
-
Pharma, Biotech Stocks Surge as Trump's Draft Order on Drug Prices Seen as Favorable (IBB) (XBI)
-
SPDR S&P Biotech ETF (XBI) volatility low into BIO International Convention )
-
Chardan Capital Markets Upgrades Akari Therapeutics (AKTX) to Neutral
-
Today's Biotech Upside Could Be Just the Start - BMO Capital (IBB) (XBI)
-
Biotech, Pharma Stocks Surge as IPAB Not Triggered
-
UPDATE: Some Large ETFs Halted on NYSE Arca Technical Issues
-
Speculators On the Lookout for the Next Big Biotech Deal After ABBV/PCYC; J&J Seen on the Prowl
-
Biotech ETFs Surge on Reports of Another Sector Deal (IBB) (XBI)
-
Wall Street Looks to Soothe Biotech's Holiday Meltdown (GILD) (CELG) (AMGN)
-
Celgene (CELG), Related Stocks Decline Amid Biopharma Weakness
-
Traders Rotate Out of Biotech after Month Long Rally (XBI) (INCY) (REGN)
-
S&P Biotech EFT (XBI) Pops on Amylin (AMLN) Buyout News
-
Biotech Sector ETFs Could See Big Day on GILD/VRUS Deal
-
Notable ETF Movers 3/01: FXI, XBI, SPY, XHB, MOO Up; TAN, UNG, EWU Down
-
ETF Movers: Biotech ETFs On the Moves Following ImClone Offer

